A Gut Microbe Could Hold a Key to Help People Benefit from Healthy Foods
Study reveals higher gut levels of Blastocystis in people who have better cardiometabolic health and a healthier diet.
Contact Information
Wang Building, 5th Floor
15 Parkman Street
Boston,
MA
02114
Phone: 617-726-6609
Hours: Monday–Friday, 8:00 am–5:00 pm
Using state-of-the-art technology and leading-edge medical and surgical interventions, the Diagnostic and Therapeutic Gastroenterology Program provides patients with a timely diagnosis of their condition as well as individualized, ongoing care for the entire spectrum of gastrointestinal disease.
The Diagnostic and Therapeutic Gastroenterology Program at the Massachusetts General Hospital offers comprehensive detection, treatment and management options for patients with acute and chronic gastrointestinal conditions.
We treat patients for the full range of conditions, including:
Patients with Crohn’s disease and colitis are treated through the Crohn’s and Colitis Center.
Patients with liver conditions are treated through the Liver Center.
After referral and initiation of therapy, the Diagnostic and Therapeutic Gastroenterology Program works closely with both the patient and the referring physician on long-term care plans to ensure the best possible outcomes.
In addition to personal care from our gastroenterologists, we offer a team approach that taps into the expertise of other specialists including:
The care team works with both the patient and the referring physician to coordinate a care plan designed to offer the best outcomes.
The Diagnostic and Therapeutic Gastroenterology Center offers the most advanced screenings and treatments currently available for a wide variety of gastrointestinal disorders. In addition to standard screening procedures, including colonoscopy, we offer patients access to cutting-edge techniques, some of which we have helped to pioneer, including:
We offer outpatients and inpatients a quick turnaround and expert analysis of their test findings, 24 hours a day, for a range of diagnostic and therapeutic procedures. Our specialists are available around the clock to confer with referring physicians.
Our diagnostic radiology team is composed of dedicated imaging specialists whose practice focuses specifically on GI scans. They are nationally recognized for expertise in all forms of sophisticated imaging, including: CT scans, PET scans, MRI scans, and interventional procedures.
Minimally invasive treatments often present additional options for patients who required traditional open surgery in the past. Our colleagues in the Department of Surgery offer these new techniques that have the benefit of faster recovery times, smaller surgical scars and greater nerve preservation.
The Diagnostic and Therapeutic Gastroenterology Center has extensive experience treating many types of gastrointestinal cancers. We treat esophageal, gastric, pancreatic, liver, colorectal and anal cancers with chemotherapy and/or radiation in the Tucker Gosnell Center for Gastrointestinal Cancers. Our patients benefit from the expertise of a highly skilled radiation oncology team that makes use of the latest multimodality treatments.
Pelvic floor disorders are often under-reported and under-diagnosed because many patients feel uncomfortable talking about their symptoms or assume they can’t be corrected. Our specialists can accurately recognize and manage many conditions, including prolapse and incontinence.
We provide patients and referring physicians with an experienced access coordinator, a clinician who helps assess patient needs, coordinate appointments and begin the appropriate testing regimen.
Contact the Center’s access coordinator
Calls will be returned within 24 hours.
Our center is ranked consistently as a top program in the country.
Our Magnet® award-winning nursing staff offers excellence in care at every step of the patient experience.
The Diagnostic and Therapeutic Gastroenterology Program at Massachusetts General Hospital is a leader in the diagnosis and treatment of primary motility and continence disorders and rectal/bowel problems that arise following surgery. We are a resource for patients who have had unsuccessful treatments and surgeries for conditions including diverticulitis and chronic anal disease.
Our physicians are active in clinical trials and research studies related to acute and chronic colorectal conditions, allowing us to bring our patients promising new treatments as quickly as possible.
Along with several area hospitals, we are part of a Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancer. Our patients may benefit from being able to take part in this multimillion-dollar National Cancer Institute-funded research program.
Patients interested in participating in clinical trials can browse online for open trials.
Our gastroenterologists, hepatologists, endoscopists and advanced practice providers are dedicated to the prevention, diagnosis, treatment and management of digestive diseases and gastrointestinal malignancies. Possessing expertise in all aspects of digestive health, our multidisciplinary team of specialists offers patients the benefit of an individualized treatment plan.
Meet our team >>
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
Study reveals higher gut levels of Blastocystis in people who have better cardiometabolic health and a healthier diet.
Hanseul Kim, PhD, is the lead author of a recently published research letter in the journal Gastroenterology, Altered Microbial Transcription in Long-Term Proton Pump Inhibitor Usage: Findings From a US Cohort Study
Results warrant additional studies into the health benefits of aspirin for patients with metabolic dysfunction–associated steatotic liver disease.
Andrew Chan, MD, MPH is co-leading the global team known as PROSPECT, which received a grant of up to $25m over five years, to study early-onset colorectal cancer from Cancer Grand Challenges after an international competition.
In a nationally representative of US adults with self-reported chronic liver disease (CLD), approximately 308,000 (6%) identified delaying medical care due to transportation barriers.
Michael Dougan, MD, PhD, is a senior author of a new study in Clinical Gastroenterology and Hepatology, Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis.